Business
Anixa Biosciences Announces Notice of Allowance of Additional Patent on Ovarian Cancer Vaccine Technology
SAN JOSE, Calif., July 27, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the
About this update from Anixa Biosciences, Inc.
[{"type":"text","content":"SAN JOSE, Calif., July 27, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. (\"Anixa\" or the \"Company\") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance broadening protection of Anixa's novel ovarian cancer vaccine technology, which has been exclusively licensed from, and is being developed in partnership with, Cleveland Clinic. \n\n \n \n \n \n \n \n\n \nThe patent is titled \"Ovarian Cancer Vaccines,\" and covers nucleic acid-based delivery of the vaccine. The lead inventor is the late Dr. Vincent Tuohy of Cleveland Clinic.\nThis ovarian cancer vaccine targets the extracellular domain of anti-Müllerian hormone receptor 2 (AMHR2-ED), which is expressed in the ovaries but disappears as a woman reaches and advances through menopause. However, AMHR2-ED is expressed again in the majority of ovarian cancers.\nDr. Amit Kumar, Chairman and CEO of Anixa, stated, \"We are pleased to receive this notice of allowance from the USPTO, providing additional protection for our ovarian cancer vaccine technology, including a possible mRNA vaccine.\" Dr. Kumar added, \"Preclinical work to advance the vaccine is ongoing with support from the PREVENT Program at the National Cancer Institute (NCI), which supports preclinical innovative interventions and biomarkers for cancer prevention and interception.\"\nAbout Anixa Biosciences, Inc.Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of an ovarian cancer immunotherapy program that uses a novel type of CAR-T known as chimeric endocrine receptor T-cell (CER-T) technology, and is being developed in collaboration with Moffitt Cancer Center. The Company's vaccine portfolio includes a novel vaccine being developed in collaboration with Cleveland Clinic to prevent breast cancer – specifically triple negative breast cancer (TNBC), the most lethal form of the disease – as well as a vaccine to prevent ovarian cancer. These vaccine technologies focus on immunizing against \"retired\" proteins that have been found to be expressed in certain forms of cancer. Anixa's unique business model of partnering with world-renowned research institutions on clinical development allows the Company to ...